A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

A common blood test may miss ovarian ... the National Cancer Institute and published Thursday in JAMA Network Open, looked at a test called CA-125. The test measures a tumor marker in the blood ...

The cancer diagnostics market was valued at $168,600.04 million in 2020, and is projected to reach $280,590.21 million by 2028, registering a CAGR of 6.9% from 2021 to 2028. The major factor that ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

Objective Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood.

Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...